# Similar Organizations Database & Benchmarking

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Strategy Officer
**Purpose**: Comprehensive analysis of peer organizations in rare disease advocacy‚Äîbenchmark operations, programs, fundraising, and identify best practices to accelerate Mark Egly Foundation's growth and impact

---

## üìã Table of Contents

1. [Benchmarking Overview](#benchmarking-overview)
2. [Tier 1: Premier Models](#tier-1-premier-models)
3. [Tier 2: Similar-Size Rare Disease Foundations](#tier-2-similar-size-rare-disease-foundations)
4. [Tier 3: Respiratory Disease Organizations](#tier-3-respiratory-disease-organizations)
5. [Key Metrics Comparison](#key-metrics-comparison)
6. [Best Practices Analysis](#best-practices-analysis)
7. [Application to Mark Egly Foundation](#application-to-mark-egly-foundation)
8. [Strategic Recommendations](#strategic-recommendations)

---

## Benchmarking Overview

### Why Benchmark?

**Learn from Success**:

- Avoid reinventing wheel (proven models exist‚Äîadapt, don't start from scratch)
- Accelerate growth (compress 20-year learning curve into 5 years‚Äîstudy what works)
- Set realistic goals (understand what's achievable‚Äîrevenue, programs, timeline)
- Identify gaps (see what we're missing‚Äîprograms, partnerships, fundraising strategies)

**Who to Study**:

- **Tier 1**: Aspirational models (Michael J. Fox, CF Foundation‚Äî30+ years, $100M+ budgets, massive impact)
- **Tier 2**: Similar-size peers (PH Association, LAM Foundation‚Äî$5M-$20M budgets, rare diseases, 10-20 years old)
- **Tier 3**: Adjacent space (American Lung Association, COPD Foundation‚Äîlung disease focus, different scale/model)

---

### Benchmarking Dimensions

**Operational Metrics**:

- Budget size (total revenue‚Äîgives sense of scale)
- Staff size (FTEs‚Äîhow many people deliver programs?)
- Years in operation (maturity‚Äîhow long to reach current state?)
- Overhead ratio (admin + fundraising / total expenses‚Äîefficiency benchmark)

**Program Metrics**:

- Patient services (types, reach‚Äîhow many patients served?)
- Research funding ($ committed to research‚Äîpriority level)
- Advocacy wins (legislation passed, policies changed‚Äîinfluence)

**Fundraising Metrics**:

- Revenue mix (individual, corporate, events, grants‚Äîdiversification)
- Donor retention rate (% who give year-over-year‚Äîsustainability)
- Major gifts (# of $10K+ donors‚Äîconcentration vs. broad base)
- Cost to raise $1 (efficiency‚Äîhow much spent on fundraising per dollar raised?)

**Innovation Metrics**:

- Unique programs (what do they do that no one else does?‚Äîdifferentiators)
- Technology adoption (patient portals, telehealth, AI‚Äîmodernization)
- Partnerships (pharma, academic, corporate‚Äîcollaborative vs. siloed)

---

## Tier 1: Premier Models

### 1. Michael J. Fox Foundation for Parkinson's Research

**Overview**:

- **Founded**: 2000 (25 years old)
- **Budget**: $150M+ annually (2023)
- **Staff**: ~100 FTEs
- **Mission**: Cure Parkinson's disease through research funding, clinical trial acceleration, patient engagement

**Why They're the Gold Standard**:

- Largest nonprofit funder of Parkinson's research ($1.5B+ awarded since founding)
- Celebrity founder (Michael J. Fox‚Äîinstant credibility, media access, donor attraction)
- Business-minded approach (fund research like venture capital‚Äîmilestone-driven, results-oriented)
- Patient registry (Fox Trial Finder‚Äî90,000+ patients, accelerates clinical trial enrollment)

---

**Revenue Model** (2023):

- Individual donations: $90M (60%‚Äîdirect mail, online, major gifts)
- Events: $40M (27%‚ÄîNYC gala [$20M], regional events)
- Corporate/foundation grants: $20M (13%‚Äîpharma, biotech partnerships)

**Overhead**: 11% (excellent‚Äî89% goes to programs, research)

**Key Programs**:

1. **Research Grants**: $120M/year (basic science, drug development, clinical trials‚Äîrigorous peer review, milestone-based funding)
2. **Fox Trial Finder**: Patient registry + clinical trial matching (90K patients enrolled‚Äîpharma partners use for recruitment)
3. **Patient Resources**: Educational materials, webinars, support groups (secondary to research‚Äîbut well-executed)
4. **PPMI Study**: Parkinson's Progression Markers Initiative ($100M longitudinal study‚Äîtracking 1,000+ patients, open-access data for all researchers)

**Fundraising Best Practices**:

- **Celebrity leverage**: Michael J. Fox appears at events, on TV, in fundraising appeals (star power = massive ROI)
- **Major donor cultivation**: Dedicated team for $100K+ donors (personalized stewardship, research briefings, insider access)
- **Event excellence**: NYC Gala raises $20M (single night‚Äî500 attendees, $10K+ tickets, A-list entertainment, live auction)
- **Corporate partnerships**: Pharma companies fund research (Abbvie, Biogen, Roche‚Äîco-investment in drug development, shared goals)

**What Mark Egly Foundation Can Learn**:

- ‚úÖ **Registry as asset**: Fox Trial Finder accelerates trials (Foundation should build AATD Patient Registry‚Äîsee separate document)
- ‚úÖ **Business approach to research**: Fund like investor (milestones, accountability‚Äînot open-ended academic grants)
- ‚úÖ **Celebrity/champion**: If Foundation can recruit prominent AATD patient (athlete, actor, business leader‚Äîamplifies reach)
- ‚úÖ **Events at scale**: Start with $100K gala, build to $1M+ over 5-10 years (Fox model proves it's possible)

**What's Not Applicable**:

- ‚ùå Celebrity founder (Foundation doesn't have Michael J. Fox‚Äîbut can identify AATD champions)
- ‚ùå $150M budget (unrealistic for AATD‚Äîpatient population smaller [25K vs. 1M Parkinson's]‚Äîceiling likely $20M-$50M)

---

### 2. Cystic Fibrosis Foundation

**Overview**:

- **Founded**: 1955 (70 years old)
- **Budget**: $500M+ annually (2023‚Äîincludes drug royalties)
- **Staff**: ~300 FTEs
- **Mission**: Cure cystic fibrosis, improve quality of life for CF patients

**Why They're Legendary**:

- Venture philanthropy pioneers (invested $150M in Vertex Pharmaceuticals‚Äîdeveloped Kalydeco, Orkambi, Trikafta [CF drugs])
- Royalty model (CF Foundation owns royalties on Trikafta‚Äî$500M/year revenue, funds organization in perpetuity)
- Care center network (120 CF clinics nationwide‚Äîaccredited by Foundation, ensures quality care)
- Patient registry (40,000 patients‚Äîmost comprehensive CF database, drives research)

---

**Revenue Model** (2023):

- Drug royalties: $450M (90%‚ÄîTrikafta sales, unprecedented for nonprofit)
- Individual donations: $30M (6%)
- Corporate/foundation grants: $15M (3%)
- Events: $5M (1%)

**Overhead**: 8% (exceptional‚Äî92% to programs)

**Key Programs**:

1. **Research Funding**: $100M/year (drug development, gene therapy, basic science)
2. **Therapeutics Development**: Venture philanthropy (invest in biotech companies‚Äîtake equity, royalty rights)
3. **Care Center Network**: 120 clinics (accreditation standards, quality metrics‚Äîensures all CF patients have access to excellent care)
4. **Patient Registry**: 40,000 patients (clinical data‚Äîtracks outcomes, identifies trends, informs research)
5. **Compass Program**: Insurance navigation, financial assistance (help patients access Trikafta, augmentation therapy‚Äîco-pay support, appeals)

**Fundraising Best Practices**:

- **Chapter model**: 60 local chapters (grassroots fundraising‚Äîevents, community engagement, volunteer-driven)
- **Great Strides Walk**: National walk series (raises $30M/year‚Äî50,000+ walkers across 200 cities)
- **Corporate partnerships**: Pharma companies donate (Vertex, Abbvie‚Äîbeyond royalties, direct grants)

**What Mark Egly Foundation Can Learn**:

- ‚úÖ **Venture philanthropy**: Invest in gene therapy, drug development (if Foundation invests $5M in AATD gene therapy startup, negotiate royalties‚Äîpotential perpetual funding like CF Foundation)
- ‚úÖ **Care center accreditation**: Foundation could accredit AATD clinics (quality standards, data sharing‚Äîimprove care consistency)
- ‚úÖ **Patient registry**: CF model is gold standard (Foundation should build similar‚Äîsee registry document)
- ‚úÖ **Chapter model**: Consider regional chapters (Cleveland, Boston, LA‚Äîlocal events, grassroots fundraising)

**What's Not Applicable**:

- ‚ùå $500M drug royalties (CF Foundation got lucky‚ÄîTrikafta is blockbuster [$6B/year sales], unlikely Foundation will replicate, but worth trying!)
- ‚ùå 70-year history (CF Foundation had decades to build‚ÄîFoundation needs faster path)

---

### 3. Muscular Dystrophy Association (MDA)

**Overview**:

- **Founded**: 1950 (75 years old)
- **Budget**: $160M annually (2023)
- **Staff**: ~200 FTEs
- **Mission**: Cure muscular dystrophy, ALS, related neuromuscular diseases

**Key Features**:

- **Labor Day Telethon**: Iconic fundraiser (Jerry Lewis hosted 1966-2010‚Äîraised $2.6B+ over 44 years, retired 2014)
- **Research grants**: $40M/year (largest funder of neuromuscular research‚Äîoutside NIH)
- **Care centers**: 150+ MDA clinics (multidisciplinary care‚Äîneurology, PT, RT, social work)
- **Summer camp**: Free week-long camps for kids with MD (50 camps, 3,000 kids/year‚Äîrespite for families, normalcy for kids)

**Revenue Model** (2023):

- Individual donations: $100M (63%‚Äîdirect mail, legacy gifts)
- Events: $30M (19%‚ÄîMuscle Walks, golf tournaments, regional galas)
- Corporate grants: $20M (12%)
- Government grants: $10M (6%)

**What Mark Egly Foundation Can Learn**:

- ‚úÖ **Summer camp model**: AATD family retreat (see separate document‚Äîsimilar concept, smaller scale)
- ‚úÖ **Care center network**: Accredit AATD clinics (standardize care, improve outcomes)
- ‚úÖ **Muscle Walk**: MDA's national walk series (Foundation's Breathe Easy Walk mirrors this‚Äîproven model)

**What's Less Relevant**:

- ‚ùå Telethon model (outdated‚ÄîJerry Lewis was unique, TV viewership declining, modern fundraising is digital)

---

## Tier 2: Similar-Size Rare Disease Foundations

### 4. Pulmonary Hypertension Association (PHA)

**Overview**:

- **Founded**: 1990 (35 years old)
- **Budget**: $8M annually (2023)
- **Staff**: ~30 FTEs
- **Patient population**: ~40,000 PH patients in US (similar to AATD‚Äî25,000 diagnosed)

**Why They're a Good Peer Benchmark**:

- Similar budget (Foundation's 5-year target: $5M-$10M‚ÄîPHA is there now)
- Rare lung disease (overlap with AATD‚Äîrespiratory, chronic, life-threatening)
- Strong patient services + research focus (balanced approach‚Äînot just advocacy or just research)

---

**Revenue Model** (2023):

- Individual donations: $4M (50%)
- Pharma/corporate grants: $2.5M (31%‚ÄîUnited Therapeutics, Janssen, others)
- Events: $1M (13%)
- Government grants: $500K (6%)

**Overhead**: 22% (reasonable‚Äî78% to programs)

**Key Programs**:

1. **Support Groups**: 250+ support groups nationwide (in-person + virtual‚Äîpeer support, education)
2. **Patient Conference**: Annual conference (1,000+ attendees‚Äîpatients, families, clinicians, researchers)
3. **Research Grants**: $500K/year (seed grants for early-stage PH research)
4. **Advocacy**: Legislation (Right Heart Awareness Act‚Äîfederal PH research funding, passed 2023)
5. **Accredited Centers**: 60 PH care centers (Foundation accredits‚Äîensures quality, collects data)

**What Mark Egly Foundation Can Learn**:

- ‚úÖ **Support group network**: PHA has 250 groups (Foundation should aim for 100+ by Year 5‚Äîsee support group document)
- ‚úÖ **Annual conference**: PHA's 1,000-attendee conference (Foundation's Year 5 target: 500+ attendees‚Äîsee conference document)
- ‚úÖ **Pharma funding**: PHA gets $2.5M from pharma (Foundation should target Grifols, CSL Behring, Takeda‚Äîaugmentation therapy manufacturers)
- ‚úÖ **Accredited centers**: PHA model works (Foundation should accredit AATD clinics‚Äî60-80 nationwide)

**Budget Timeline**:

- PHA at 35 years: $8M budget
- Foundation target: Reach $5M-$8M by Year 10 (compress timeline‚Äîlearn from PHA's successes/failures, skip what didn't work)

---

### 5. LAM Foundation (Lymphangioleiomyomatosis)

**Overview**:

- **Founded**: 1995 (30 years old)
- **Budget**: $5M annually (2023)
- **Staff**: ~15 FTEs
- **Patient population**: ~5,000 LAM patients in US (ultra-rare lung disease, women only)

**Why They Punch Above Their Weight**:

- Small budget, big impact (funded research that led to FDA approval of Rapamycin for LAM‚Äîonly approved treatment)
- Lean operations (15 FTEs‚Äîefficient, focused)
- Patient registry (1,000+ patients‚Äî25% of US LAM population, impressive penetration)

---

**Revenue Model** (2023):

- Individual donations: $2.5M (50%)
- Events: $1.5M (30%‚Äîannual walk, gala)
- Corporate/foundation grants: $1M (20%)

**Key Programs**:

1. **Research Grants**: $1M/year (small grants, but strategic‚Äîfunded pivotal trials)
2. **Patient Registry**: 1,000+ patients (LAM Registry‚Äîlongitudinal data, natural history)
3. **LAM Clinics**: 25 specialized clinics (Foundation-designated‚Äînot formal accreditation, but listed as "LAM experts")
4. **Education**: Webinars, conferences, newsletters (standard patient ed)

**What Mark Egly Foundation Can Learn**:

- ‚úÖ **Lean model**: LAM Foundation does a lot with 15 FTEs (Foundation should stay lean‚Äî30-40 FTEs max by Year 10)
- ‚úÖ **Strategic research funding**: Don't need huge budget (LAM funded FDA-approval trial with <$1M‚Äîsmart bets > big bets)
- ‚úÖ **Registry penetration**: 1,000 of 5,000 patients = 20% (Foundation target: 5,000 of 25,000 AATD patients = 20% by Year 5‚Äîachievable)

---

### 6. National Organization for Rare Disorders (NORD)

**Overview**:

- **Founded**: 1983 (42 years old)
- **Budget**: $30M annually (2023)
- **Scope**: Umbrella organization (7,000+ rare diseases‚Äînot disease-specific)
- **Staff**: ~50 FTEs

**Programs**:

1. **Patient Assistance**: $15M/year (co-pay support for rare disease drugs‚ÄîFoundation could learn model)
2. **Advocacy**: Orphan Drug Act (NORD lobbied for 1983 passage‚Äîwatershed moment for rare disease)
3. **Research**: Small grants ($50K-$100K‚Äîseed funding)
4. **Database**: Rare Disease Database (comprehensive info on 1,300+ diseases‚ÄîAATD included)

**What Mark Egly Foundation Can Learn**:

- ‚úÖ **Co-pay assistance model**: NORD provides $15M/year (Foundation should offer augmentation therapy co-pay assistance‚Äîsee financial assistance document)
- ‚úÖ **Coalition-building**: NORD unites rare disease community (Foundation should join coalitions‚ÄîEveryLife Foundation, Genetic Alliance)

**What's Different**:

- NORD is broad (7,000 diseases‚ÄîFoundation is laser-focused on AATD, deeper not wider)

---

## Tier 3: Respiratory Disease Organizations

### 7. American Lung Association

**Overview**:

- **Founded**: 1904 (121 years old)
- **Budget**: $60M annually (2023)
- **Staff**: ~250 FTEs
- **Scope**: All lung diseases (asthma, COPD, lung cancer, TB‚Äîbroad mission)

**Programs**:

1. **Tobacco control**: Anti-smoking campaigns ($20M/year‚Äîbiggest program)
2. **Research**: $10M/year (lung cancer, COPD, asthma)
3. **Advocacy**: Clean air legislation (EPA regulations, smoke-free laws)
4. **Events**: Fight for Air Climb, Lung Force Walk ($15M/year)

**What Mark Egly Foundation Can Learn**:

- ‚úÖ **Event portfolio**: ALA has multiple event types (climb, walk, cycle‚ÄîFoundation should diversify beyond just Walk)
- ‚úÖ **Corporate sponsorships**: ALA gets major corporate sponsors (CVS, Anthem‚ÄîFoundation should target healthcare companies)

**What's Not Applicable**:

- ‚ùå Broad mission (ALA is all lung diseases‚ÄîFoundation benefits from narrow focus, deep expertise in AATD)

---

### 8. COPD Foundation

**Overview**:

- **Founded**: 2004 (21 years old)
- **Budget**: $20M annually (2023)
- **Staff**: ~60 FTEs
- **Patient population**: 16M COPD patients in US (overlaps with AATD‚Äîmany AATD patients have COPD)

**Programs**:

1. **Patient-Powered Research Network (PPRN)**: 20,000+ COPD patients (registry, surveys, research participation)
2. **COPD360social**: Online community (10,000+ members‚Äîpeer support, Q&A)
3. **Advocacy**: COPD National Action Plan (federal initiative‚ÄîCOPD Foundation led effort)
4. **Research**: $2M/year (COPD studies, clinical trials)

**What Mark Egly Foundation Can Learn**:

- ‚úÖ **Online community**: COPD360social is excellent (Foundation should build similar‚Äîsee Alpha1Life.com document)
- ‚úÖ **PPRN model**: 20,000-patient registry (Foundation should aim for 10,000 AATD patients‚Äîsee registry document)

**Collaboration Opportunity**:

- Many AATD patients have COPD (overlap in patient population‚ÄîFoundation should partner with COPD Foundation, not compete)

---

## Key Metrics Comparison

### Budget Size (Annual Revenue)

| Organization               | Budget | Age (Years) | Budget/Year  |
| -------------------------- | ------ | ----------- | ------------ |
| **CF Foundation**          | $500M  | 70          | $7.1M/year   |
| **Michael J. Fox**         | $150M  | 25          | $6M/year     |
| **MDA**                    | $160M  | 75          | $2.1M/year   |
| **American Lung**          | $60M   | 121         | $496K/year   |
| **COPD Foundation**        | $20M   | 21          | $952K/year   |
| **PHA**                    | $8M    | 35          | $229K/year   |
| **LAM Foundation**         | $5M    | 30          | $167K/year   |
| **Mark Egly (Target Y5)**  | $5M    | 5           | **$1M/year** |
| **Mark Egly (Target Y10)** | $10M   | 10          | **$1M/year** |

**Insight**: Foundation's Y10 target ($10M) would put us between COPD Foundation and PHA‚Äîambitious but realistic

---

### Staff Size vs. Budget

| Organization               | Budget | Staff (FTEs) | Budget/FTE      |
| -------------------------- | ------ | ------------ | --------------- |
| **CF Foundation**          | $500M  | 300          | $1.67M          |
| **Michael J. Fox**         | $150M  | 100          | $1.5M           |
| **American Lung**          | $60M   | 250          | $240K           |
| **PHA**                    | $8M    | 30           | $267K           |
| **LAM Foundation**         | $5M    | 15           | $333K           |
| **Mark Egly (Target Y5)**  | $5M    | 20-25        | **$200K-$250K** |
| **Mark Egly (Target Y10)** | $10M   | 35-40        | **$250K-$286K** |

**Insight**: Foundation's efficiency target aligns with PHA (lean operations, $250K-$300K per FTE)

---

### Research Funding (% of Budget to Research)

| Organization              | Budget | Research $ | Research %                     |
| ------------------------- | ------ | ---------- | ------------------------------ |
| **Michael J. Fox**        | $150M  | $120M      | **80%** (research-dominant)    |
| **CF Foundation**         | $500M  | $100M      | 20% (plus venture investments) |
| **MDA**                   | $160M  | $40M       | 25%                            |
| **PHA**                   | $8M    | $500K      | 6% (patient services dominant) |
| **LAM Foundation**        | $5M    | $1M        | 20%                            |
| **Mark Egly (Target Y5)** | $5M    | $1M        | **20%** (balanced model)       |

**Insight**: Foundation should aim for 15-25% to research (balanced‚Äînot pure research like MJF, not pure services like PHA)

---

### Overhead Ratio (Admin + Fundraising / Total Expenses)

| Organization           | Overhead % | Rating         |
| ---------------------- | ---------- | -------------- |
| **CF Foundation**      | 8%         | Exceptional    |
| **Michael J. Fox**     | 11%        | Excellent      |
| **LAM Foundation**     | 18%        | Good           |
| **PHA**                | 22%        | Reasonable     |
| **American Lung**      | 25%        | Acceptable     |
| **Industry Average**   | 25-30%     | Typical        |
| **Mark Egly (Target)** | **15-20%** | Good-Excellent |

**Insight**: Foundation should target 15-20% overhead (below average, signals efficiency to donors)

---

## Best Practices Analysis

### Fundraising

**Michael J. Fox Foundation: Major Donor Excellence**

- **Practice**: Dedicated major gifts team (10 FTEs‚Äîsolely focused on $100K+ donors)
- **Result**: 60% of revenue from individuals (concentrated in major gifts)
- **Application**: Foundation should hire Major Gifts Officer by Year 3 (when donor base matures‚Äîfocus on 5-figure+ donors)

**CF Foundation: Chapter Model**

- **Practice**: 60 local chapters (volunteer-led‚Äîgrassroots fundraising, community events)
- **Result**: $30M/year from Great Strides Walk (distributed across 60 chapters)
- **Application**: Foundation could pilot 3-5 chapters by Year 5 (Cleveland, Boston, LA, Phoenix, Tampa‚Äîhigh AATD populations)

**PHA: Pharma Partnerships**

- **Practice**: Deep relationships with PH drug manufacturers (United Therapeutics, Janssen‚Äîco-invest in research, sponsor programs)
- **Result**: $2.5M/year from pharma (31% of budget‚Äînot over-reliant, but significant)
- **Application**: Foundation should cultivate Grifols, CSL Behring, Takeda (augmentation manufacturers‚Äîsponsor patient programs, research)

---

### Patient Services

**PHA: Support Group Network**

- **Practice**: 250 support groups (in-person + virtual‚Äîvolunteer facilitators, Foundation provides training, materials)
- **Result**: 5,000+ patients engaged (community building‚Äîreduced isolation, peer support)
- **Application**: Foundation target 100 groups by Year 5 (see support group document)

**COPD Foundation: Online Community**

- **Practice**: COPD360social (10,000+ members‚ÄîQ&A forums, expert chats, private messaging)
- **Result**: 24/7 peer support (scales better than phone line‚Äîmembers help each other)
- **Application**: Foundation should build Alpha1Life.com (see community platform document)

**MDA: Summer Camp**

- **Practice**: Free week-long camps for kids with MD (50 camps, 3,000 kids/year‚Äîrespite for families)
- **Result**: Quality of life improvement (kids feel "normal," families get break‚Äîhard to quantify but transformative)
- **Application**: Foundation could pilot AATD Family Retreat (see patient education document‚Äîweekend vs. week-long, smaller scale)

---

### Research Strategy

**Michael J. Fox: Milestone-Driven Funding**

- **Practice**: Grant milestones (release funds in stages‚Äî$500K upfront, $500K after Year 1 data, $500K after publication)
- **Result**: Accountability (researchers deliver or lose funding‚Äîaccelerates progress)
- **Application**: Foundation should adopt for research grants (not open-ended‚Äîstructured milestones, performance-based)

**CF Foundation: Venture Philanthropy**

- **Practice**: Invest in biotech ($150M in Vertex‚Äîequity + royalties)
- **Result**: $500M/year royalties from Trikafta (perpetual funding‚Äîhome run)
- **Application**: Foundation should invest $2M-$5M in AATD gene therapy startup (negotiate royalties‚Äîlow probability of CF-level success, but worth shot)

**LAM Foundation: Strategic Small Grants**

- **Practice**: $50K-$100K pilot grants (seed promising ideas‚Äîlow risk, high potential)
- **Result**: LAM-funded research led to Rapamycin approval (small investment, massive impact)
- **Application**: Foundation should offer $50K pilot grants (5-10 per year‚Äîdiversify research portfolio, find hidden gems)

---

### Advocacy

**NORD: Coalition-Building**

- **Practice**: Unite rare disease community (1,300+ diseases‚Äîcollective advocacy, shared resources)
- **Result**: Orphan Drug Act (1983‚Äîwatershed legislation, enabled rare disease drug development)
- **Application**: Foundation should join coalitions (EveryLife Foundation, Genetic Alliance‚Äîamplify voice, access policymakers)

**PHA: Legislative Wins**

- **Practice**: Focused advocacy (Right Heart Awareness Act‚Äîspecific, achievable goal)
- **Result**: Federal PH research funding increased (NIH allocation‚Äîdirect benefit to patients)
- **Application**: Foundation should pursue AATD-specific legislation (see advocacy documents‚Äînewborn screening, research funding)

---

## Application to Mark Egly Foundation

### Hybrid Model: Best of All Worlds

**Foundation's Positioning**:

- **Research focus** (like Michael J. Fox‚Äî20% of budget, milestone-driven, venture philanthropy)
- **Patient services** (like PHA‚Äîsupport groups, conference, registry)
- **Lean operations** (like LAM‚Äî$200K-$300K per FTE, efficient)
- **Pharma partnerships** (like CF Foundation‚Äîengage augmentation manufacturers)

---

### 5-Year Roadmap (Inspired by Benchmarks)

**Year 1-2: Foundation Phase** (Build Infrastructure)

- Budget: $1M-$2M (startup mode‚Äîmajor donors, seed grants)
- Staff: 5-10 FTEs (lean team‚ÄîED, Development Director, Program Manager, admin)
- Programs: Launch 2-3 core services (Patient Navigation, Support Groups, Education)
- Fundraising: Major gifts focus (5-10 donors @ $100K+), pilot Walk event ($100K)

**Year 3-4: Growth Phase** (Scale Programs)

- Budget: $3M-$5M (double annually‚Äîexpand donor base, increase events)
- Staff: 15-20 FTEs (add specialists‚ÄîResearch Director, Advocacy Director, Marketing Manager)
- Programs: Launch registry (target 1,000 patients), annual conference (250 attendees), research grants ($500K/year)
- Fundraising: Diversify (events $500K, individuals $2M, pharma $500K, foundations $500K)

**Year 5: Maturity Phase** (Optimize & Innovate)

- Budget: $5M-$8M (sustainable‚Äîrecurring revenue streams established)
- Staff: 20-25 FTEs (fully-staffed‚Äîall functions covered)
- Programs: 50+ support groups, 3,000 registry patients, $1M research/year, 3-5 legislative wins
- Fundraising: Major gifts mature (20-30 @ $100K+), events at scale ($1M+), pharma partnerships ($1M-$2M)

---

### Year 10 Aspiration (Learn from CF, MJF)

**Budget**: $10M-$15M (top-tier rare disease foundation)
**Programs**:

- Registry: 10,000 patients (40% of diagnosed AATD population‚Äîgold standard like CF)
- Research: $2M-$3M/year (major funder‚Äîon par with NIH for AATD)
- Advocacy: Newborn screening in 25+ states (policy wins‚Äîimpact millions)
- Patient services: 200+ support groups, patient navigation in all 50 states, annual conference 1,000+ attendees

**Funding Model**:

- Individuals: $5M (major gifts, planned giving‚Äîloyal donor base)
- Pharma: $3M (Grifols, CSL, Takeda partnerships‚Äîco-invest in programs, research)
- Events: $2M (Walk, Gala, Virtual‚Äîmature event portfolio)
- Foundations: $1M (NIH, private foundations‚Äîgrants)
- Royalties/IP: $1M-$3M (if venture philanthropy pays off‚Äîgene therapy, diagnostics)

---

## Strategic Recommendations

### Recommendation 1: Adopt Milestone-Based Research Funding (MJF Model)

**Action**: Structure grants with performance milestones (Year 1: preliminary data, Year 2: publication, Year 3: clinical trial)
**Timeline**: Implement Year 2 (when research program launches)
**Investment**: No additional cost (just structure of existing research budget)
**Impact**: Faster research progress (accountability drives results)

---

### Recommendation 2: Build Patient Registry (CF/PHA Model)

**Action**: Launch AATD Patient Registry (see separate document‚Äî10,000-patient target by Year 10)
**Timeline**: Year 2-3 launch, 5-year growth plan
**Investment**: $500K setup + $200K/year operations
**Impact**: Accelerate clinical trials (pharma partnerships), natural history data (guide treatment), donor engagement (tangible asset)

---

### Recommendation 3: Pursue Venture Philanthropy (CF Model)

**Action**: Invest $2M-$5M in AATD gene therapy startup (negotiate equity + royalties)
**Timeline**: Year 5-7 (when Foundation has capital, gene therapy nearing approval)
**Investment**: $2M-$5M (high-risk capital‚Äîmay lose all, or may generate CF-level returns)
**Impact**: If successful, perpetual funding (royalties sustain Foundation forever‚Äîworth the risk)

---

### Recommendation 4: Establish Pharma Partnerships (PHA Model)

**Action**: Formalize relationships with Grifols, CSL Behring, Takeda (augmentation manufacturers)
**Timeline**: Year 1-2 (early priority‚Äîpartnerships take time to develop)
**Investment**: Staff time (BD efforts‚Äîno cash outlay)
**Impact**: $1M-$3M/year by Year 5 (corporate grants, research co-funding, event sponsorships)

---

### Recommendation 5: Stay Lean (LAM Model)

**Action**: Cap staff at 35-40 FTEs by Year 10 (resist urge to over-hire‚Äîefficiency matters)
**Timeline**: Ongoing discipline
**Investment**: N/A (cost savings‚Äîlower overhead)
**Impact**: 15-20% overhead ratio (donor confidence‚Äî"My donation goes to patients, not bureaucracy")

---

## Summary

**Learn from the Best, Adapt to AATD**:

- ‚úÖ **Research excellence** (MJF‚Äîmilestone-driven, venture approach)
- ‚úÖ **Patient services** (PHA‚Äîsupport groups, conference, registry)
- ‚úÖ **Venture philanthropy** (CF‚Äîinvest in gene therapy, negotiate royalties)
- ‚úÖ **Lean operations** (LAM‚Äî$200K-$300K per FTE, efficient)
- ‚úÖ **Pharma partnerships** (PHA‚Äîco-invest with industry, mutual benefit)

**10-Year Vision**: $10M-$15M budget, 10,000-patient registry, $3M/year research funding, 200+ support groups, gene therapy investment (potential perpetual funding)

**"Stand on the shoulders of giants. Then reach higher."**

---

**Learn More**

**Mark Egly Foundation Strategic Planning**
üìß Email: strategy@markeglyfoundation.org
üìû Phone: (XXX) XXX-XXXX
üåê Website: MarkEglyFoundation.org

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"We study the best to become the best."_

**‚Äî Mark Egly Foundation**
